Abstract
Aberrant epidermal growth factor (EGF) receptor (EGFR) signaling contributes to neoplastic initiation and progression in lung. Mutated EGFR has become as an important therapeutic target in lung cancer, whereas targeted treatment is not available for wild-type EGFR or its ligands. In this study, we found that heparin-binding (HB)-EGF, a member of the EGF family, was highly expressed in a subset of lung cancer, proliferation of which was dependent on HB-EGF signaling. Silencing of HB-EGF with RNA interference inhibited cell cycle progression in lung cancer cells. We observed that, upon HB-EGF induction, CITED4 was induced through a signal transducer and activator of transcription 3 (STAT3)-dependent pathway, regulating cell proliferation. CITED4 interacted with MYC and potentiated MYC-mediated transactivation of the CCND1 promoter, leading to cell cycle progression. Correlation analysis revealed that HB-EGF and CITED4 were significantly positively associated in primary lung tumors, and expression of HB-EGF predicted a poor survival outcome in patients. In vitro and in vivo experiments revealed that pharmacological inhibition of HB-EGF with CRM197 significantly attenuated tumor cell growth. Thus, CITED4 functions as a molecular switch in HB-EGF-induced growth control, and HB-EGF provides a novel therapeutic target for lung cancer intervention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gazdar AF, Minna JD . Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res 2008; 1: 156–160.
Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379–2385.
Sharma SV, Bell DW, Settleman J, Haber DA . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169–181.
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005; 65: 11478–11485.
Volante M, Saviozzi S, Rapa I, Ceppi P, Cappia S, Calogero R et al. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer 2007; 110: 1321–1328.
Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N et al. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 2007; 6: 2652–2663.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14: 981–988.
Laurie SA, Goss GD . Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Ocol 2013; 31: 1061–1069.
Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C et al. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 2003; 22: 2704–2716.
Leslie CC, McCormick-Shannon K, Shannon JM, Garrick B, Damm D, Abraham JA et al. Heparin-binding EGF-like growth factor is a mitogen for rat alveolar type II cells. Am J Respirat Cell Mol Biol 1997; 16: 379–387.
Wang Y, Maciejewski BS, Soto-Reyes D, Lee HS, Warburton D, Sanchez-Esteban J . Mechanical stretch promotes fetal type II epithelial cell differentiation via shedding of HB-EGF and TGF-alpha. J Physiol 2009; 587: 1739–1753.
Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M . A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936–939.
Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M et al. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995; 6: 967–980.
Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M . Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994; 202: 1705–1709.
Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N et al. Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 1998; 96: 322–328.
Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64: 5720–5727.
Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005; 11: 4783–4792.
Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E . A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61: 6227–6233.
Boyle S, Shioda T, Perantoni AO, de Caestecker M . Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dynamics 2007; 236: 2321–2330.
Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC et al. Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem 2002; 277: 8559–8565.
Qu X, Lam E, Doughman YQ, Chen Y, Chou YT, Lam M et al. Cited2, a coactivator of HNF4alpha, is essential for liver development. EMBO J 2007; 26: 4445–4456.
Weninger WJ, Lopes Floro K, Bennett MB, Withington SL, Preis JI, Barbera JP et al. Cited2 is required both for heart morphogenesis and establishment of the left-right axis in mouse development. Development 2005; 132: 1337–1348.
Yahata T, Takedatsu H, Dunwoodie SL, Braganca J, Swingler T, Withington SL et al. Cloning of mouse Cited4, a member of the CITED family p300/CBP-binding transcriptional coactivators: induced expression in mammary epithelial cells. Genomics 2002; 80: 601–613.
Chou YT, Wang H, Chen Y, Danielpour D, Yang YC . Cited2 modulates TGF-beta-mediated upregulation of MMP9. Oncogene 2006; 25: 5547–5560.
Chou YT, Yang YC . Post-transcriptional control of Cited2 by transforming growth factor beta. Regulation via Smads and Cited2 coding region. J Biol Chem 2006; 281: 18451–18462.
Dunwoodie SL, Rodriguez TA, Msg1 Beddington RS . and Mrg1, founding members of a gene family, show distinct patterns of gene expression during mouse embryogenesis. Mech Dev 1998; 72: 27–40.
Li H, Ahmed NU, Fenner MH, Ueda M, Isselbacher KJ, Shioda T . Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells. Exp Cell Res 1998; 242: 478–486.
Sun HB, Zhu YX, Yin T, Sledge G, Yang YC . MRG1, the product of a melanocyte-specific gene related gene, is a cytokine-inducible transcription factor with transformation activity. Proc Natl Acad Sci USA 1998; 95: 13555–13560.
Chou YT, Hsieh CH, Chiou SH, Hsu CF, Kao YR, Lee CC et al. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence. Cell Death Differ 2012; 19: 2015–2028.
Fox SB, Braganca J, Turley H, Campo L, Han C, Gatter KC et al. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res 2004; 64: 6075–6081.
Bostrom P, Mann N, Wu J, Quintero PA, Plovie ER, Panakova D et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010; 143: 1072–1083.
Ryall KA, Bezzerides VJ, Rosenzweig A, Saucerman JJ . Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J Mol Cell Cardiol 2014; 72: 74–84.
Wei X, Liu X, Rosenzweig A . What do we know about the cardiac benefits of exercise? Trends Cardiovasc Med 2015; 25: 529–536.
Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004; 64: 5283–5290.
Harada D, Takigawa N, Kiura K . The role of STAT3 in non-small cell lung cancer. Cancers 2014; 6: 708–722.
Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ . Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 1994; 9: 3635–3645.
Vinante F, Rigo A . Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor in normal and neoplastic hematopoiesis. Toxins 2013; 5: 1180–1201.
Naef M, Yokoyama M, Friess H, Buchler MW, Korc M . Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996; 66: 315–321.
Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005; 92: 1737–1745.
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
Kageyama T, Ohishi M, Miyamoto S, Mizushima H, Iwamoto R, Mekada E . Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J Biochem 2007; 142: 95–104.
Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997; 17: 353–360.
Acknowledgements
This research was supported by National Yang-Ming University, National Tsing Hua University, the Institute of Biomedical Sciences, Academia Sinica and the Ministry of Science and Technology (MOST104-2321-B-010-007 and MOST103-2320-B-007-006-MY3), Executive Yuan, Taiwan, ROC.
Author contributions
C-HH performed the experiments, analyzed the data and wrote the manuscript. Y-TC designed the experiments, collected the data, conducted the interpretation of data and wrote the manuscript. M-HK analyzed the public domain data. H-PT provided the clinical samples. J-LC scored the RISH result of clinical samples. C-WW supervised this study.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Hsieh, CH., Chou, YT., Kuo, MH. et al. A targetable HB-EGF–CITED4 axis controls oncogenesis in lung cancer. Oncogene 36, 2946–2956 (2017). https://doi.org/10.1038/onc.2016.465
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2016.465
This article is cited by
-
Serum biomarkers associated with SARS-CoV-2 severity
Scientific Reports (2022)
-
Heparin-binding epidermal growth factor contributes to COPD disease severity by modulating airway fibrosis and pulmonary epithelial–mesenchymal transition
Laboratory Investigation (2018)